Cisplatin drug page Clinical trials

Trials with Cisplatin

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

43Trials
13Recruiting
35Countries
11.364Planned patients

Showing 1–20 of 43

AK129 Combination Therapy for Advanced Solid Tumors
Recruiting Phase 1 230 patients NCT06943820

This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations f…

China May 2025 – May 2028 Interventional
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Recruiting Phase 1 154 patients NCT06657144

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

United States, Taiwan Apr 2025 – Jan 2028 Interventional
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Recruiting Phase 1 220 patients NCT06428409

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…

United States, Australia, Canada, Chile and 7 more Jun 2024 – Oct 2029 Interventional
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Recruiting Phase 1 616 patients NCT06162221

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…

United States, Australia, Denmark, France and 6 more Jan 2024 – Dec 2028 Interventional
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Recruiting Phase 1 351 patients NCT06241456

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epiderma…

United States Jan 2024 – May 2044 Interventional
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Recruiting Phase 2 454 patients NCT05489211

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

United States, Canada, China, France and 7 more Sept 2022 – Oct 2027 Interventional
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Recruiting Phase 1 442 patients NCT05410145

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combinat…

United States, Australia, China, France and 6 more Aug 2022 – Apr 2027 Interventional
A Study of ASP3082 in Adults With Advanced Solid Tumors
Recruiting Phase 1 681 patients NCT05382559

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a…

United States, China, France, Japan and 3 more Jun 2022 – Dec 2028 Interventional
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Recruiting Phase 1 60 patients NCT04847063

Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that…

United States Oct 2021 – Dec 2034 Interventional
AB122 Platform Study
Recruiting Phase 1 917 patients NCT04999761

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

Japan Jun 2021 – Jun 2027 Interventional
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Recruiting Phase 1 49 patients NCT04329494

This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the lining of the a…

United States Aug 2020 – Jan 2028 Interventional
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Recruiting Phase 1 99 patients NCT03965234

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delive…

United States Jul 2020 – May 2030 Interventional
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Recruiting Phase 1 1.006 patients NCT04389632

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

United States, France, South Korea, Spain and 3 more Jun 2020 – Mar 2029 Interventional
Combined with: CarboplatinPembrolizumab
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
Not yet recruiting Phase 1 159 patients NCT06724042

This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients with advance…

Jun 2026 – Jun 2030 Interventional
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Not yet recruiting Phase 1 350 patients NCT06594874

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, espec…

China Oct 2024 – Jan 2027 Interventional
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Ongoing, not recruiting Phase 1 750 patients NCT06607185

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alo…

United States, Belgium, France, Germany and 4 more Oct 2024 – Jan 2030 Interventional
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ongoing, not recruiting Phase 1 340 patients NCT06561685

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid …

United States, France, Germany, Japan and 2 more Sept 2024 – Oct 2027 Interventional
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Ongoing, not recruiting Phase 1 540 patients NCT04956640

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…

United States, Australia, Canada, France and 2 more Jul 2021 – Apr 2027 Interventional
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Ongoing, not recruiting Phase 1 320 patients NCT04495296

This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled. The study will consist of two parts: Part A is dose escalation and dose expansion phase for mono-ther…

China Aug 2020 – Dec 2026 Interventional
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Ongoing, not recruiting Phase 1 350 patients NCT04083599

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain ty…

United States, Denmark, France, Georgia and 7 more Sept 2019 – Jan 2027 Interventional

Where the recruiting trials are